Toll Free: 1-888-928-9744

Drug Overdose - Pipeline Review, H2 2017

Published: Sep, 2017 | Pages: 48 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Drug Overdose - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Drug Overdose - Pipeline Review, H2 2017, provides an overview of the Drug Overdose (Toxicology) pipeline landscape.

Drug overdoses occur when a person takes more than the medically recommended dose of a prescription or over-the-counter drug. It can be either accidental or intentional. Symptoms include sleepiness, confusion, chest pain, seizures, abdominal pain, nausea, vomiting, and diarrhea. Risk factors include age, gender, mental illness and history of overdose. Treatment includes antidote and activated charcoal. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Drug Overdose - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Drug Overdose (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Drug Overdose (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Drug Overdose and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 1, 1, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Drug Overdose (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Overdose (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Drug Overdose (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Drug Overdose (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Drug Overdose (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Drug Overdose (Toxicology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Drug Overdose (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Drug Overdose (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Drug Overdose - Overview Drug Overdose - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Drug Overdose - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Drug Overdose - Companies Involved in Therapeutics Development Fab'entech SA Insys Therapeutics Inc Klaria Pharma Holding AB Opiant Pharmaceuticals Inc Drug Overdose - Drug Profiles Antibody for Poisoning, Drug Overdose and Opioid Addiction - Drug Profile Product Description Mechanism Of Action R&D Progress FBT-001 - Drug Profile Product Description Mechanism Of Action R&D Progress melatonin - Drug Profile Product Description Mechanism Of Action R&D Progress naloxone hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress naloxone hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress naloxone hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress naloxone hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress naloxone hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule for Drug Overdose - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine for Drug Overdose - Drug Profile Product Description Mechanism Of Action R&D Progress Drug Overdose - Dormant Projects Drug Overdose - Discontinued Products Drug Overdose - Product Development Milestones Featured News & Press Releases Aug 10, 2017: Opiant Pharmaceuticals Announces Additional $3.75 Million Payment From NARCAN Nasal Spray Royalty Monetization Aug 04, 2017: Opiant Pharmaceuticals Announces FDA Orange Book Listing for New NARCAN Nasal Spray Patent Jun 18, 2017: ResQ Pharma Receives FDA Orphan Drug Designation for LipidRescue Therapy for the Treatment of Local Anesthetic Systemic Toxicity Jun 06, 2017: Survey Data Published on Community Use of NARCAN (naloxone HCI) Nasal Spray 4 mg to Help Reverse Opioid-Related Overdose - Current Medical Research and Opinion Journal Apr 24, 2017: Emergency opioid treatment NARCAN Nasal Spray added to NIHB Program in Canada Apr 11, 2017: Ontario ministries make NARCAN Nasal Spray available to general public Apr 10, 2017: Adapt Pharma Expands Free NARCAN Nasal Spray Program to U.S. Colleges and Universities Mar 27, 2017: Opiant Pharmaceuticals Announces Results of Positron Emission Tomography Study of Naloxone Nasal Spray Mar 16, 2017: New Data Presented on Adapt Pharmas Community Use of Narcan Nasal Spray 4 mg to Reverse Opioid-Related Overdose Mar 15, 2017: Mucodel Pharma Announces Patent Allowance for Mucodel's Co-Gel Buccal Naloxone (Exonal) Mar 09, 2017: Opiant Pharmaceuticals Announces FDA Orange Book Listings for Two New NARCAN Nasal Spray Patents Feb 28, 2017: Adapt Pharma Marks One-Year Anniversary of NARCAN Nasal Spray (naloxone HCl) 4mg Launch in the U.S. Feb 21, 2017: Adapt Pharma Announces European Marketing Application Filed For Naloxone Hydrochloride Nasal Spray Jan 30, 2017: Kroger Pharmacies to Increase Access to Naloxone in North Texas, East Texas and Southeast Texas Jan 11, 2017: Opiant Pharmaceuticals Announces 2017 Corporate and Clinical Goals Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Drug Overdose, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Drug Overdose - Pipeline by Fab'entech SA, H2 2017 Drug Overdose - Pipeline by Insys Therapeutics Inc, H2 2017 Drug Overdose - Pipeline by Klaria Pharma Holding AB, H2 2017 Drug Overdose - Pipeline by Opiant Pharmaceuticals Inc, H2 2017 Drug Overdose - Dormant Projects, H2 2017 Drug Overdose - Discontinued Products, H2 2017



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify